RL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RL is not a good buy right now for an impatient buyer. The stock is sitting just above near-term support (351.8) but momentum is still deteriorating (bearish MACD expansion) and options positioning is defensively skewed into the Feb-5 earnings event. Despite strong fundamentals and bullish/raising Street targets, the current tape suggests you’re more likely to face short-term churn/downside than an immediate upside follow-through. I would hold off on new buying until price reclaims the pivot area (362+) and momentum stabilizes.
Price/levels: RL at 352.6 is hovering just above S1 support (351.811) and below the pivot (362.312), implying the stock is trading in the lower part of its near-term range. Momentum: MACD histogram at -1.814 is below zero and negatively expanding, signaling bearish momentum is still building rather than bottoming. RSI(6) at 34.38 is near oversold-territory (weak/washed-out), which can spark bounces, but without a MACD turn it’s more of a ‘falling knife’ setup than a clean reversal. Moving averages are converging, consistent with consolidation/transition—however, the momentum read currently favors sellers. Key levels: downside supports at 351.8 then 345.3; upside resistance at 362.3 (pivot) then 372.8 and 379.3. Near-term pattern stats provided are mixed/weak (only modest edge in the next day/month).
shows strong acceleration (revenue +16.49% YoY, EPS +44.16% YoY) plus gross margin expansion. Wall Street tone: Multiple firms have raised targets recently while reiterating Buy/Overweight/Outperform, supporting dips if results/guidance stay strong.
reflect defensive sentiment into the event. Technical pressure: Bearish MACD expansion indicates sellers still control the short-term trend; if 351.8 breaks, next support is ~345.3 with limited structure in between.
Latest quarter: 2026/Q2. Growth and profitability trends are strong: revenue $2.0107B (+16.49% YoY), net income $207.5M (+40.30% YoY), EPS $3.33 (+44.16% YoY). Gross margin improved to 67.96% (+1.49% YoY), reinforcing that the brand/mix and pricing power are translating into better profitability, not just top-line growth.
Recent trend: Clear positive skew—multiple price target increases and Buy/Overweight reiterations across UBS (up to $474), Deutsche Bank (Buy, $422), Barclays (Overweight, $409), Telsey (Outperform, $435), Wells Fargo (Overweight, up to $400), Jefferies (Buy, $425). Only notable moderation is Guggenheim initiating at Neutral (no PT). Wall Street pros: consistent execution, brand elevation, margin strength, and resilient demand narrative. Cons: sector demand uncertainty and the stock’s already-strong run (~40% in 12 months per news) raises the bar for earnings/guidance. Trading/flow checks: Hedge funds and insiders are reported neutral; no recent Congress trading data available.
